Chemotherapy-Induced Neutropenia

Understanding, monitoring, and preventing the most common dose-limiting toxicity of cytotoxic chemotherapy

Key Points

• Neutropenia (ANC <1,500/μL) is the most common dose-limiting toxicity of cytotoxic chemotherapy; severe neutropenia (ANC <500/μL) carries the highest infection risk.
• The nadir — the lowest ANC after chemotherapy — typically occurs 7–14 days after a myelosuppressive regimen; timing varies by agent.
• G-CSF agents (filgrastim, pegfilgrastim) reduce the depth and duration of neutropenia and are recommended prophylactically when the risk of febrile neutropenia exceeds 20%.
• Granulocyte colony-stimulating factor (G-CSF) should NOT be started within 24 hours before or after myelosuppressive chemotherapy due to the risk of stimulating cells in cycle.
• Common culprits for severe myelosuppression include anthracyclines, taxanes, platinum agents, gemcitabine, and topoisomerase inhibitors.
• Patients with neutropenia should avoid raw foods, crowded settings, and anyone who is ill; hand hygiene is the single most effective infection prevention strategy.

Pathophysiology and Definition

Chemotherapy-induced neutropenia (CIN) results from direct cytotoxic damage to hematopoietic progenitor cells in the bone marrow. Cytotoxic agents target rapidly dividing cells, and myeloid precursors — which divide frequently to maintain the peripheral neutrophil pool — are particularly vulnerable. The result is suppression of granulopoiesis, leading to a fall in circulating neutrophils over the days to weeks following chemotherapy administration. Neutrophils are the primary cellular defenders against bacterial and fungal infections. When their numbers fall, the risk of serious infection…

High-Risk Chemotherapy Regimens and Agents

Not all chemotherapy regimens carry the same myelosuppressive risk. The risk of febrile neutropenia — the most clinically significant consequence — is used as the primary benchmark. **High-risk regimens (>20% febrile neutropenia risk — G-CSF prophylaxis recommended):** - Dose-dense AC → paclitaxel (breast cancer) - TAC (docetaxel, doxorubicin, cyclophosphamide) — breast cancer - CHOP-21/RCHOP with dose-dense variations - Hyper-CVAD (acute leukemia) - BEP (bleomycin, etoposide, cisplatin) — testicular cancer - Topotecan-containing regimens - Vinorelbine/cisplatin combinations (NSCLC)…

G-CSF Prophylaxis and Treatment

Granulocyte colony-stimulating factors (G-CSFs) stimulate the bone marrow to produce and release neutrophils, reducing the depth and duration of chemotherapy-induced neutropenia. Their use has transformed the management of neutropenia and enabled dose-dense chemotherapy regimens. **Available G-CSF agents:** - **Filgrastim** (Neupogen; biosimilars: Zarxio, Nivestym, Releuko): short-acting; given daily by subcutaneous injection starting 24–72 hours after chemotherapy completion; continued until ANC recovery (typically 10–14 days) - **Pegfilgrastim** (Neulasta; biosimilars: Fulphila, Udenyca,…

Monitoring and Dose Modifications

Routine CBC monitoring is essential for all patients receiving myelosuppressive chemotherapy. The typical schedule: - Baseline CBC before each cycle - Mid-cycle nadir CBC (e.g., day 10–14) for high-risk regimens - Pre-treatment CBC within 24–72 hours before scheduled treatment Chemotherapy should generally be held or dose-reduced if the ANC on the day of treatment is <1,000–1,500/μL (institution- and protocol-specific thresholds). Dose reductions are typically 25% for grade 3 neutropenic complications and 25–50% for grade 4 or febrile neutropenia, depending on the clinical intent (curative…

Infection Prevention: What Patients Can Do

During periods of neutropenia, patients are highly vulnerable to bacterial, fungal, and occasionally viral infections. Patient education is a critical component of neutropenia management. **Hand hygiene:** Frequent and thorough handwashing with soap and water (or alcohol-based sanitizer) is the most effective single intervention. Patients should wash hands before eating, after using the bathroom, and after any contact with potentially contaminated surfaces. **Avoiding infection sources:** - Avoid crowded public places during nadir period, especially during peak respiratory virus season -…